tirzepatide renal impairment SURPASS-4: slows kidney disease in adults with type 2 diabetes, CV risk is tirzepatide hard on kidneys

People who use reduced appetite to build better habits tend to have better outcomes

GMP Certified

These treatments offer solutions to reduce unwanted fat and cellulite, catering to patients who are either apprehensive about surgery or who are not at the point of needing more invasive treatments

Dose Escalation Schedule: First 20 Weeks (Escalation Phase): Weeks 1-4: 2.5 mg weekly (all groups) Weeks 5-8: 5 mg weekly Weeks 9-12: 7.5 mg weekly (for 10 mg and 15 mg groups) Weeks 13-16: 10 mg weekly (for 10 mg and 15 mg groups) Weeks 17-20: 12.5 mg weekly (for 15 mg group only) Week 21+: Maintenance dose (5 mg, 10 mg, or 15 mg) Primary Results (72 Weeks): Weight Loss by Dose: Key Findings (15 mg Dose): Percentage of Patients Achieving Weight Loss Milestones: 5% weight loss: 96% (vs 28% placebo) 10% weight loss: 89% (vs 16% placebo) 15% weight loss: 78% (vs 9% placebo) 20% weight loss: 63% (vs 3% placebo) 25% weight loss: 50% (vs 1% placebo) These are the best weight loss results ever achieved in a clinical trial for any medication